QbD-driven development of intranasal lipid nanoparticles for depression treatment-Reference-Cited by-同舟云学术

QbD-driven development of intranasal lipid nanoparticles for depression treatment

Published:2020-08 Issue: Volume:153 Page:106-120
ISSN:0939-6411
Container-title:European Journal of Pharmaceutics and Biopharmaceutics
language:en
Short-container-title:European Journal of Pharmaceutics and Biopharmaceutics

Author:

Vitorino Carla,Silva Soraia,Gouveia Filipa,Bicker Joana,Falcão Amílcar,Fortuna Ana

Funder

FEDER

FCT

PIDDAC

Publisher

Elsevier BV

Subject

Pharmaceutical Science,General Medicine,Biotechnology

Reference54 articles.

1. WHO, Depression, in, 2018.

2. Faster, better, stronger: towards new antidepressant therapeutic strategies;O'Leary;Eur. J. Pharmacol.,2015

3. Mordorintelligence, Global Antidepressant Market, in, 2018.

4. Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials;Sum;Int. J. Neuropsychopharmacol.,2015

5. Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders;Forte;J. Affect Disord.,2015

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoliposomal in situ gel of fluoxetine and embelin as a potent intervention for depression via the intranasal route in CUMS animal model;Journal of Drug Delivery Science and Technology;2024-09

2. Microfluidics-on-a-chip for designing celecoxib-based amorphous solid dispersions: when the process shapes the product;Drug Delivery and Translational Research;2024-06-11

3. Lipid engineered nanomaterials: A novel paradigm shift for combating stroke;Applied Materials Today;2024-06

4. Rheological and Injectability Evaluation of Sterilized Poloxamer-407-Based Hydrogels Containing Docetaxel-Loaded Lipid Nanoparticles;Gels;2024-05-01

5. Intranasal delivery of paroxetine: A preclinical study on pharmacokinetics, depressive-like behaviour, and neurochemical sex differences;Biochemical Pharmacology;2024-05